Leica Biosystems announced on August 11, 2026 that it had secured multiple FDA 510(k) clearances for its digital pathology portfolio, headlined by what the company calls the industry’s first standalone, AI-assisted quality control software for clinical digital pathology. The tool, Aperio iQC DX, doesn’t diagnose disease at all — its entire job is catching bad slide scans before a pathologist ever has to read them, and according to real-world data cited by the company, it detects up to 24% more artifacts than histotechnicians catch on their own while cutting hands-on review time by 69%.
The unglamorous problem nobody solved
Digital pathology depends on turning a physical glass slide into a high-resolution digital scan, and that conversion process is fragile. Air bubbles trapped under the coverslip, stray pen marks, tissue that gets clipped at the edge of the scan field, tissue missing entirely from a corner, regions that come out of focus, and image striping from scanner artifacts can all silently degrade a scan in ways that are easy for a busy histotechnician to miss during a quick visual check. A pathologist who then reads a compromised digital slide risks reaching a diagnosis based on distorted or incomplete tissue — a quiet failure mode that traditional quality checks haven’t fully solved.
What the AI actually catches
Aperio iQC DX automatically screens for six specific artifact categories — air bubbles, pen marks, clipped tissue, missing tissue, out-of-focus regions, and image striping — while the slide is still sitting on the scanner. That timing matters: catching a bad scan immediately means the slide can be rescanned on the spot, rather than discovering the problem later in the pathologist’s workflow, after the slide has already been removed and possibly returned to storage, making a rescan far more disruptive. Leica says its real-world data shows the AI models catch up to 24% more artifacts than histotechnicians identify through manual visual inspection, while reducing the hands-on review time needed to check each slide by 69%.
Part of a bigger hardware push
The AI quality control software arrived alongside two other clearances: the Aperio GT 180 DX, a mid-volume clinical scanner with 180-slide capacity, and an enhanced Aperio GT 450 DX high-throughput scanner adding manual scan capability, more advanced DICOM support, and z-stacking for multi-layer focus imaging. Naveen Chandra, Leica Biosystems’ vice president and general manager of digital pathology, framed the clearances as leadership in moving digital pathology “beyond individual products toward connected, standardized workflows” — positioning the company less as a scanner vendor and more as a full pipeline provider from slide to diagnosis.
Why quality control, not diagnosis, is the real bottleneck
Much of the public conversation about AI in pathology focuses on diagnostic algorithms that flag cancer or grade tumors, but lab directors have increasingly pointed to a more mundane bottleneck: the sheer operational strain of scanning, checking, and often re-scanning thousands of slides a day as digital pathology adoption grows and case volumes rise faster than staffing. A tool that reduces rescans and catches artifacts a tired histotechnician might miss addresses that operational strain directly, without requiring the same clinical validation burden as a diagnostic AI claim, which may explain why Leica pursued this as a standalone quality-control clearance rather than bundling it into a diagnostic product.
The skeptical view
Some laboratory quality assurance specialists caution that automating artifact detection could create a different kind of complacency: if histotechnicians come to rely on the software as a backstop, manual review standards could erode over time, and any gap in the AI’s own detection — the six categories it targets are specific, not exhaustive — could let a different kind of scan problem slip through unnoticed. Leica’s answer is that the tool is meant to supplement, not replace, existing quality checks, catching issues while the slide is still accessible for immediate rescanning rather than serving as the sole line of defense.
What’s next for pathology labs
The clearance reflects where FDA-authorized pathology AI is heading in 2026: not just diagnostic algorithms grabbing headlines, but a maturing ecosystem of AI tools addressing every step of the digital pathology pipeline, from scanning hardware to quality assurance to prognostic risk scoring. For hospital pathology departments facing rising case volumes and persistent staffing shortages, tools like Aperio iQC DX offer a way to squeeze more throughput and consistency out of existing staff — a less dramatic story than an AI that spots cancer, but arguably one that determines whether the diagnostic AI tools built on top of these scans can be trusted in the first place.
